☆ 4.7 Review

The efficacy and adverse effects of favipiravir on patients with COVID-19: A systematic review and meta-analysis of published clinical trials and observational studies

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Infectious Diseases

Baseline uric acid levels and steady-state favipiravir concentrations are associated with occurrence of hyperuricemia among COVID-19 patients

Takenao Koseki et al.

Summary: This study found that steady-state concentrations of favipiravir in COVID-19 patients were significantly correlated with serum uric acid levels. High baseline uric acid levels and steady-state concentrations of favipiravir during therapy were identified as risk factors for hyperuricemia.

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2022)

添加到收藏夹

Article Immunology

AVIFAVIR for Treatment of Patients With Moderate Coronavirus Disease 2019 (COVID-19): Interim Results of a Phase II/III Multicenter Randomized Clinical Trial

Andrey A. Ivashchenko et al.

Summary: In May 2020, AVIFAVIR, an RNA polymerase inhibitor, was granted fast-track marketing authorization by the Russian Ministry of Health for the treatment of COVID-19 patients. In the pilot stage of Phase II/III clinical trial, AVIFAVIR demonstrated a 62.5% viral clearance rate within 4 days for SARS-CoV-2 patients and was shown to be safe and well-tolerated.

CLINICAL INFECTIOUS DISEASES (2021)

添加到收藏夹

Article Medicine, Research & Experimental

Tocilizumab combined with favipiravir in the treatment of COVID-19: A multicenter trial in a small sample size

Hong Zhao et al.

Summary: The study found that tocilizumab combined with or without favipiravir can effectively improve pulmonary inflammation in COVID-19 patients, alleviate clinical symptoms, and help blood routine return to normal.

BIOMEDICINE & PHARMACOTHERAPY (2021)

添加到收藏夹

Article Pharmacology & Pharmacy

Clinical Outcomes and Plasma Concentrations of Baloxavir Marboxil and Favipiravir in COVID-19 Patients: An Exploratory Randomized, Controlled Trial

Yan Lou et al.

Summary: Effective antiviral drugs for COVID-19 are still lacking and this study aimed to evaluate the clinical outcomes and plasma concentrations of baloxavir acid and favipiravir in COVID-19 patients. In vitro evaluation showed that baloxavir acid exhibited antiviral activity, while favipiravir did not demonstrate significant antiviral activity. However, the addition of either baloxavir marboxil or favipiravir under the trial dosages did not show clear benefits compared to standard treatment.

EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2021)

添加到收藏夹

Article Virology

Effectiveness of remdesivir for the treatment of hospitalized COVID-19 persons: A network meta-analysis

Yawen Jiang et al.

Summary: The study aimed to synthesize available RCT evidence on the effectiveness of remdesivir for treating hospitalized COVID-19 patients using network meta-analyses. Both the 10-day and 5-day remdesivir regimens were associated with higher odds of clinical improvement and recovery compared to a placebo. This suggests that remdesivir may have clinical benefits for hospitalized COVID-19 patients.

JOURNAL OF MEDICAL VIROLOGY (2021)

添加到收藏夹

Letter Virology

Tolerability of favipiravir therapy in critically ill patients with COVID-19: A report of four cases

Nicolas Dauby et al.

JOURNAL OF MEDICAL VIROLOGY (2021)

添加到收藏夹

Letter Dermatology

Fluorescence of nails and hair on Wood's lamp examination in Covid pandemic; undefined effect of Favipiravir in humans

Melek Aslan Kayiran et al.

DERMATOLOGIC THERAPY (2021)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Six-month Follow-up Chest CT Findings after Severe COVID-19 Pneumonia

Xiaoyu Han et al.

Summary: The study found that over one-third of severe COVID-19 patients showed fibrotic-like changes in the lung at 6-month follow-up CT, which were associated with older age, acute respiratory distress syndrome, longer hospital stays, tachycardia, noninvasive mechanical ventilation, and higher initial chest CT score.

RADIOLOGY (2021)

添加到收藏夹

Article Immunology

Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pneumonia

Masoud Solaymani-Dodaran et al.

Summary: The study found that adding Favipiravir to the treatment protocol did not reduce ICU admissions, intubations, or in-hospital mortality compared to the Lopinavir/Ritonavir regimen. There were also no significant differences in time to clinical recovery and length of hospital stay between the two treatment groups.

INTERNATIONAL IMMUNOPHARMACOLOGY (2021)

添加到收藏夹

Article Infectious Diseases

Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial

Zarir F. Udwadia et al.

Summary: The study aimed to assess the efficacy and safety of favipiravir in adults with mild-to-moderate COVID-19. Results showed a significant improvement in time to clinical cure with favipiravir, although there was no statistically significant difference in viral shedding cessation time.

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2021)

添加到收藏夹

Article Infectious Diseases

Suspected cholestatic liver injury induced by favipiravir in a patient with COVID-19

Shingo Yamazaki et al.

Summary: Favipiravir is an antiviral drug expected to have therapeutic effects on SARS-CoV2 infection, but can cause cholestatic liver injury in high doses. In this case, high dose favipiravir may have exacerbated pre-existing liver dysfunction.

JOURNAL OF INFECTION AND CHEMOTHERAPY (2021)

添加到收藏夹

Editorial Material Infectious Diseases

Remdesivir for the treatment of coronavirus COVID-19: A meta-analysis of randomised controlled trials

Yuki Enoki et al.

JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE (2021)

添加到收藏夹

Article Infectious Diseases

Clinical and CT features of mild-to-moderate COVID-19 cases after two sequential negative nucleic acid testing results: a retrospective analysis

Yan Rong et al.

Summary: Patients with COVID-19 continued to recover even after their respiratory nucleic acid test results turned negative, but abnormal imaging findings persisted in some cases, particularly with multi-lobar lung involvement in moderate cases.

BMC INFECTIOUS DISEASES (2021)

添加到收藏夹

Article Immunology

US201 Study: A Phase 2, Randomized Proof-of-Concept Trial of Favipiravir for the Treatment of COVID-19

Robert W. Finberg et al.

Summary: Favipiravir shows enhanced viral clearance in hospitalized adult patients with COVID-19 compared to standard of care, with a median time to viral clearance of 16.0 days in the favipiravir group and 30.0 days in the SOC group. Further studies are warranted to explore its potential in treating COVID-19.

OPEN FORUM INFECTIOUS DISEASES (2021)

添加到收藏夹

Review Medicine, General & Internal

The PRISMA 2020 statement: an updated guideline for reporting systematic reviews

Matthew J. Page et al.

Summary: The PRISMA statement was designed to help systematic reviewers transparently report the purpose, methods, and findings of their reviews. The updated PRISMA 2020 statement includes new reporting guidance, a 27-item checklist, an abstract checklist, and revised flow diagrams for reviews.

BMJ-BRITISH MEDICAL JOURNAL (2021)

添加到收藏夹

Review Infectious Diseases

Favipiravir for the treatment of patients with COVID-19: a systematic review and meta-analysis

Toshie Manabe et al.

Summary: The study suggests that favipiravir shows promising efficacy in treating patients with COVID-19, inducing viral clearance within 7 days and contributing to clinical improvement within 14 days. The drug is especially effective for patients with mild-to-moderate illness. However, additional well-designed studies are needed to determine the optimal dosage and duration of treatment.

BMC INFECTIOUS DISEASES (2021)

添加到收藏夹

Article Immunology

Favipiravir in the treatment of patients with SARS-CoV-2 RNA recurrent positive after discharge: A multicenter, open-label, randomized trial

Hong Zhao et al.

Summary: The study showed that favipiravir was effective and safe in treating patients with recurrent positive SARS-CoV-2 RNA. Patients treated with favipiravir had a significantly shorter duration of viral shedding and decreased inflammatory markers. Further large-scale, randomized, double-blind, placebo-controlled trials are needed to confirm these findings.

INTERNATIONAL IMMUNOPHARMACOLOGY (2021)

添加到收藏夹

Article Virology

Benefits of treatment with favipiravir in hospitalized patients for COVID-19: a retrospective observational case-control study

Anil Ucan et al.

Summary: The study found that early initiation of Favipiravir (FPV) treatment has an impact on COVID-19 PCR negativity and disease progression, but does not significantly affect estimated survival time. Therefore, it is suggested to initiate FPV treatment promptly for better clinical outcomes in COVID-19 patients.

VIROLOGY JOURNAL (2021)

添加到收藏夹

Review Multidisciplinary Sciences

The efficacy and safety of Favipiravir in treatment of COVID-19: a systematic review and meta-analysis of clinical trials

Soheil Hassanipour et al.

Summary: The meta-analysis of Favipiravir in the treatment of COVID-19 showed significant clinical improvement in the Favipiravir group compared to the control group after seven days of hospitalization. However, there was no significant difference in viral clearance and oxygen therapy requirement between the two groups. The mortality rate was approximately 30% lower in the Favipiravir group, but this finding was not statistically significant.

SCIENTIFIC REPORTS (2021)

添加到收藏夹

Article Infectious Diseases

Favipiravir and Hydroxychloroquine Combination Therapy in Patients with Moderate to Severe COVID-19 (FACCT Trial): An Open-Label, Multicenter, Randomized, Controlled Trial

Mohammad Bosaeed et al.

Summary: The study aimed to assess the effects of a favipiravir and hydroxychloroquine combination in treating moderate-to-severe COVID-19 patients. The results showed that this combination did not result in a statistically significant clinical benefit for the patients.

INFECTIOUS DISEASES AND THERAPY (2021)

添加到收藏夹

Article Infectious Diseases

Efficacy and Safety of Favipiravir in Moderate COVID-19 Pneumonia Patients without Oxygen Therapy: A Randomized, Phase III Clinical Trial

Masaharu Shinkai et al.

Summary: The study found that favipiravir may be an option for treating moderate COVID-19 pneumonia, with better effects in patients with obesity or coexisting conditions. However, the risk of adverse events, including hyperuricemia, should be carefully considered when using favipiravir.

INFECTIOUS DISEASES AND THERAPY (2021)

添加到收藏夹

Article Respiratory System

Sustained coronavirus disease 2019-related organizing pneumonia successfully treated with corticosteroid

Hiroshi Takumida et al.

Summary: A 70-year-old Japanese man developed SARS-CoV-2 infection and required oxygen therapy 5 weeks after onset of COVID-19 symptoms. After being diagnosed with organizing pneumonia and treated with prednisolone, his respiratory symptoms improved and his respiratory function recovered. The use of corticosteroids may be considered in patients with persistent respiratory dysfunction as a sequelae of COVID-19 pneumonia.

RESPIRATORY INVESTIGATION (2021)

添加到收藏夹

Review Gastroenterology & Hepatology

The risks of liver injury in COVID-19 patients and pharmacological management to reduce or prevent the damage induced

Antonio Vitiello et al.

Summary: The global COVID-19 pandemic has caused significant deaths, particularly for elderly and those with comorbidities. Liver disease has also been identified as a potential risk factor, with the virus potentially causing direct or indirect damage to liver tissue during severe stages of the disease. Management strategies are being developed to reduce liver damage during COVID-19.

EGYPTIAN LIVER JOURNAL (2021)

添加到收藏夹

Article Pharmacology & Pharmacy

Observational study of the effects of Favipiravir vs Lopinavir/Ritonavir on clinical outcomes in critically Ill patients with COVID-19

Havva Kocayigit et al.

Summary: A study in Turkey found that the length of hospital stay was significantly shorter in patients with severe COVID-19 treated with favipiravir compared to lopinavir/ritonavir.

JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2021)

添加到收藏夹

Review Pharmacology & Pharmacy

Favipiravir, an anti-influenza drug against life-threatening RNA virus infections

Kimiyasu Shiraki et al.

PHARMACOLOGY & THERAPEUTICS (2020)

添加到收藏夹

Review Biochemical Research Methods

RNA-Dependent RNA Polymerase as a Target for COVID-19 Drug Discovery

Wei Zhu et al.

SLAS DISCOVERY (2020)

添加到收藏夹

Article Microbiology

A Prospective, Randomized, Open-Label Trial of Early versus Late Favipiravir Therapy in Hospitalized Patients with COVID-19

Yohei Doi et al.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)

添加到收藏夹

Article Pharmacology & Pharmacy

Remdesivir: First Approval

Yvette N. Lamb

DRUGS (2020)

添加到收藏夹

Article Medicine, General & Internal

Acute Gouty Arthritis During Favipiravir Treatment for Coronavirus Disease 2019

Ryota Hase et al.

INTERNAL MEDICINE (2020)

添加到收藏夹

Article Infectious Diseases

Favipiravir-induced fever in coronavirus disease 2019: A report of two cases

Hiroyuki Takoi et al.

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2020)

添加到收藏夹

Review Virology

Favipiravir versus other antiviral or standard of care for COVID-19 treatment: a rapid systematic review and meta-analysis

Dhan Bahadur Shrestha et al.

VIROLOGY JOURNAL (2020)

添加到收藏夹

Article Virology

Effect of remdesivir on patients with COVID-19: A network meta-analysis of randomized control trials

Yujiro Yokoyama et al.

VIRUS RESEARCH (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Rapid incorporation of Favipiravir by the fast and permissive viral RNA polymerase complex results in SARS-CoV-2 lethal mutagenesis

Ashleigh Shannon et al.

NATURE COMMUNICATIONS (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Potency and timing of antiviral therapy as determinants of duration of SARS-CoV-2 shedding and intensity of inflammatory response

Ashish Goyal et al.

SCIENCE ADVANCES (2020)

添加到收藏夹

Article Medicine, General & Internal

A Favipiravir-induced Fever in a Patient with COVID-19

Takashi Kurita et al.

INTERNAL MEDICINE (2020)

添加到收藏夹

Editorial Material Medicine, General & Internal

FDA Approval of Remdesivir - A Step in the Right Direction

Daniel Rubin et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Review Multidisciplinary Sciences

Efficacy and harms of remdesivir for the treatment of COVID-19: A systematic review and meta-analysis

Alejandro Piscoya et al.

PLOS ONE (2020)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

The effect of favipiravir on QTc interval in patients hospitalized with coronavirus disease 2019

Murat Cap et al.

JOURNAL OF ELECTROCARDIOLOGY (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Liver injury with COVID-19 based on gastrointestinal symptoms and pneumonia severity

Shun Kaneko et al.

PLOS ONE (2020)

添加到收藏夹

Article Medicine, General & Internal

Severe coronavirus disease 2019 (COVID-19) pneumonia patients treated successfully with a combination of lopinavir/ritonavir plus favipiravir: Case series

Hayato Koba et al.

CLINICAL CASE REPORTS (2020)

添加到收藏夹

Article Medicine, General & Internal

The effects of favipiravir on hematological parameters of covid-19 patients

Selcuk Yaylaci et al.

REVISTA DA ASSOCIACAO MEDICA BRASILEIRA (2020)

添加到收藏夹

Article Hematology

COVID-19 pneumonia in a patient with adult T-cell leukemia-lymphoma

Rika Hosoba et al.

JOURNAL OF CLINICAL AND EXPERIMENTAL HEMATOPATHOLOGY (2020)

添加到收藏夹

Review Pharmacology & Pharmacy

Systematic review and meta-analysis of effectiveness and safety of favipiravir in the management of novel coronavirus (COVID-19) patients

Ajay Prakash et al.

INDIAN JOURNAL OF PHARMACOLOGY (2020)

添加到收藏夹

Article Tropical Medicine

A step by step guide for conducting a systematic review and meta-analysis with simulation data

Gehad Mohamed Tawfik et al.

TROPICAL MEDICINE AND HEALTH (2019)

添加到收藏夹

Article Medicine, General & Internal

Antiviral efficacy of favipiravir against Ebola virus: A translational study in cynomolgus macaques

Jeremie Guedj et al.

PLOS MEDICINE (2018)

添加到收藏夹

Article Infectious Diseases

Favipiravir pharmacokinetics in Ebola-infected patients of the JIKI trial reveals concentrations lower than targeted

Thi Huyen Tram Nguyen et al.

PLOS NEGLECTED TROPICAL DISEASES (2017)

添加到收藏夹

Article Medicine, General & Internal

ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions

Jonathan A. C. Sterne et al.

BMJ-BRITISH MEDICAL JOURNAL (2016)

添加到收藏夹

Article Medicine, General & Internal

ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions

Jonathan A. C. Sterne et al.

BMJ-BRITISH MEDICAL JOURNAL (2016)

添加到收藏夹

Article Multidisciplinary Sciences

Meta-Analysis of Effect Sizes Reported at Multiple Time Points Using General Linear Mixed Model

Alfred Musekiwa et al.

PLOS ONE (2016)

添加到收藏夹

Article Health Care Sciences & Services

Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range

Xiang Wan et al.

BMC MEDICAL RESEARCH METHODOLOGY (2014)

添加到收藏夹

Article Medicine, General & Internal

The Cochrane Collaboration's tool for assessing risk of bias in randomised trials

Julian P. T. Higgins et al.

BMJ-BRITISH MEDICAL JOURNAL (2011)

添加到收藏夹

Article Pharmacology & Pharmacy

Lopinavir

M Hurst et al.

DRUGS (2000)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.